Marker Therapeutics, Inc. Stockholders Equity

• Marker Therapeutics, Inc. showed a decrease of -9.5% in Stockholders Equity from 2024 to 2025.
• This data is from Marker Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
• XBRL data for this metric is available from 2000 to 2025 (26 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2013: -$4.77 million | Q3 2013: -$5.10 million | Q2 2014: -$2.56 million | Q3 2014: -$656.2 thousand | Q1 2015: -$1.77 million | Q2 2015: -$9.81 million | Q3 2015: -$2.62 million | Q1 2016: -$25.70 million | Q2 2016: -$19.33 million | Q3 2016: $7.49 million | Q1 2017: $4.14 million | Q2 2017: $8.57 million | Q3 2017: $5.94 million | Q1 2018: $616.0 thousand | Q2 2018: $4.14 million | Q3 2018: $690.5 thousand | Q1 2019: $55.61 million | Q2 2019: $51.40 million | Q3 2019: $47.88 million | Q1 2020: $39.50 million | Q2 2020: $34.51 million | Q3 2020: $30.60 million | Q1 2021: $72.49 million | Q2 2021: $63.24 million | Q3 2021: $52.28 million | Q1 2022: $35.71 million | Q2 2022: $28.03 million | Q3 2022: $22.60 million | Q1 2023: $15.91 million | Q2 2023: $19.03 million | Q3 2023: $16.71 million | Q1 2024: $11.79 million | Q2 2024: $9.70 million | Q3 2024: $7.45 million | Q1 2025: $14.49 million | Q2 2025: $10.49 million | Q3 2025: $18.39 million.
• Over the full 26 years of available data (2000 to 2025), Marker Therapeutics, Inc.'s Stockholders Equity has grown by 6,559.4%.
• Historical annual values: Fiscal year 2025: $16.80 million | Fiscal year 2024: $18.56 million | Fiscal year 2023: $14.05 million | Fiscal year 2022: $19.60 million | Fiscal year 2021: $43.99 million | Fiscal year 2020: $27.34 million | Fiscal year 2019: $44.09 million | Fiscal year 2018: $59.34 million | Fiscal year 2017: $3.66 million | Fiscal year 2016: $6.18 million | Fiscal year 2015: -$21.36 million | Fiscal year 2014: -$1.02 million | Fiscal year 2013: -$8.77 million | Fiscal year 2012: -$6.04 million | Fiscal year 2011: -$3.46 million | Fiscal year 2010: -$3.87 million | Fiscal year 2009: -$1.78 million | Fiscal year 2008: -$3.02 million | Fiscal year 2007: -$1.67 million | Fiscal year 2006: -$3.00 million | Fiscal year 2005: -$2.22 million | Fiscal year 2004: -$2.44 million | Fiscal year 2003: -$643.7 thousand | Fiscal year 2002: $465.8 thousand | Fiscal year 2001: -$74.0 thousand | Fiscal year 2000: $252.2 thousand.
• Data sourced from SEC EDGAR public filings as of August 6, 2026.

Last verified: August 6, 2026